Human insulin drugs such as rapid-acting insulin, long-acting insulin, and premixed insulin are used for diabetes treatment. These drugs help control blood glucose levels in the body. Rising obesity levels have increased the risk of diabetes globally. According to the International Diabetes Federation, over 537 million adults are living with diabetes worldwide in 2021, and the number is expected to rise to 643 million by 2030 and 783 million by 2045. The increasing prevalence of diabetes is anticipated to boost the demand for effective treatment options like human insulin drugs over the forecast period.

The global human insulin drug market is estimated to be valued at US$ 49411.32 Mn in 2023 and is expected to exhibit a CAGR of 6.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Dynamics:
One of the key drivers for the growth of the human insulin drug market is the rising prevalence of diabetes. As mentioned above, obesity levels have increased considerably in recent years. Obesity is a major risk factor for type 2 diabetes. According to the World Health Organization (WHO), in 2016, around 1.9 billion adults aged 18 years and older were overweight, and out of these over 650 million adults were obese. If the obesity trends continue, nearly half of the world's adult population is projected to be overweight or obese by 2030. The increasing obese population subsequently raises the risk of diabetes, driving the demand for diabetes management drugs like human insulin.

Another driver for the market growth is continuous technological advancements in insulin delivery devices and treatments. Research is focused on developing new generations of rapid-acting and long-acting insulin analogs that can provide the smooth control of blood glucose levels similar to healthy pancreas. Companies are engaged in developing artificial pancreas devices and non-invasive insulin delivery technologies to make treatment more convenient for people with diabetes. These innovations are expected to boost the adoption of human insulin drugs over the projected period.

SWOT Analysis
Strength: The human insulin drug market has high unmet needs as diabetes is increasing globally. The presence of several major players in this market ensures constant innovation and development of new and advanced products. Reimbursements and awareness programs by governments further boost the adoption of human insulin drugs.
Weakness: The production of human insulin requires complex extraction and purification processes from animal sources which increases costs. Biosimilar versions also pose pricing competition to innovator brands. Side effects associated with insulin therapy and needle-phobia among patients are other challenges.
Opportunity: Rising geriatric population susceptible to diabetes coupled with obese population growth present new patient pools. The development of alternative delivery methods like inhaled insulin reduces pain and vulnerability of injections. Partnerships between players to reach untapped lower-income markets can spur growth.
Threats: Stringent regulations for approval of new drugs and changes in reimbursement policies impacts revenues. The development of alternate treatment options threatens the demand for insulin drugs. Patent expiries of key brands enable competition from biosimilars.

Key Takeaways

The global human insulin drug market is expected to witness high growth.

Regional Analysis: North America currently dominates due to the large diabetic patient pool and favorable insurance coverage in the region. However, Asia Pacific is poised to be the fastest-growing market owing to rising diabetes prevalence, growing healthcare sector and large untapped opportunities.

Key players operating in the Human Insulin Drug Market Growth are Ecolab Inc., Rollins Inc., Rentokil Initial Plc., ServiceMaster Company, LLC, Massey Services Inc., Arrow Exterminators Inc., Sanix Incorporated, Asante Inc., Dodson Pest Control, Inc., Target Specialty Products, Pelsis Ltd., Killgerm Ltd., WinField Solutions, LLC, and Univer Inc. They are focused on strengthening their product portfolios and market presence through mergers, collaborations and new product launches.

For more insights, read- https://www.pressreleasebulletin.com/human-insulin-drug-market-trends-size-and-share-analysis/